Affinity proteomics led identification of vimentin as a potential biomarker in colon cancers: insights from serological screening and computational modelling

2015 ◽  
Vol 11 (1) ◽  
pp. 159-169 ◽  
Author(s):  
Shoiab Bukhari ◽  
Taseem A. Mokhdomi ◽  
Naveed A. Chikan ◽  
Asif Amin ◽  
Hilal Qazi ◽  
...  
Keyword(s):  
Computational Modelling ◽  
Serological Screening ◽  
Immunogenic Property ◽  
Tumor Associated Antigens ◽  
Colon Cancers ◽  
Potential Biomarker ◽  
Affinity Reagent ◽  
Affinity Proteomics

Utilizing immunogenic property of antigens, an in-house affinity-reagent was developed to capture tumor associated antigens

Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11549-11549 ◽  
Author(s):  
Rachna Malani ◽  
Martin Fleisher ◽  
Xuling Lin ◽  
Antonio Marcilio Padula Omuro ◽  
Morris D. Groves ◽  
...  
Keyword(s):  
Treatment Response ◽  
Leptomeningeal Metastasis ◽  
Response To Treatment ◽  
Csf Cytology ◽  
Cellsearch System ◽  
Colon Cancers ◽  
Potential Biomarker ◽  
Pre Treatment ◽  
Assess Treatment Response ◽  
Changes Over Time

11549 Background: The validated CellSearch system (Janssen Diagnostics, LLC), utilizing an immunomagnetic CTC selection method based on EPCAM antibody conjugated ferroparticles, is an FDA-approved methodology for enumerating CTC from blood in pts with breast, prostate and colon cancers. The CellSearch system has been used to evaluate CSF CTC of pts with leptomeningeal metastasis (LM) and has demonstrated potential as a diagnostic marker and response to cancer treatment. We explored the use of CSF CTC enumeration in the follow-up of pts with LM from HER2+ cancers receiving intrathecal (IT) therapy, aimed at characterizing changes over time as a potential biomarker of treatment response. Methods: CSF from pts participating in an IRB-approved phase I/II dose escalation trial of IT trastuzumab for LM in HER2+ cancer (NCT01325207) was evaluated by CellSearch system. 3 ml CSF from a ventricular reservoir was collected for CSF CTC enumeration at pre-treatment Day 1 of each cycle and correlated with CSF cytology from the same sample, and with clinical and radiographic response. LM progression was defined as clinical, CSF cytologic or radiographic worsening. Results: 15 pts with HER2+ LM (14 breast, 1 colon) were enrolled; 13 were women. At baseline 7 pts had positive CSF cytology, the other patients had a diagnosis by MRI. Of the 15 pts, 10 had greater than 1 cycle of treatment to be evaluable; 5 pts progressed during cycle 1 (Table). Mean CSF CTC at baseline was 82 per 3ml (range 0-200); 2 pts had no detectable CSF CTCs. A numerical decrease in CSF CTC was observed in 5 pts after cycle 1 and remained low (mean =9.5, range 0-92) while disease was stable. 3 pts (pts.3, 4 and 7) demonstrated a rise in CSF CTCs roughly 1 month prior to disease progression. Conclusions: Changes in CSF CTCs enumeration in response to treatment may allow quantitative surveillance of treatment response. CSF CTCs may serve as a platform to assess treatment response or as an early biomarker of LM progression and should be further investigated. Clinical trial information: NCT01325207. [Table: see text]

scholarly journals Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Liping Dai ◽  
Jitian Li ◽  
Rosalia Ortega ◽  
Wei Qian ◽  
Carlos A. Casiano ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Early Stage ◽  
Specific Antigen ◽  
Cyclin B1 ◽  
Autoimmune Response ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Normal Prostate ◽  
Tumor Associated Antigens ◽  
Potential Biomarker

Previous studies have demonstrated that sera from patients with prostate cancer (PCa) contain autoantibodies that react with tumor-associated antigens (TAAs). Autoantibodies to cyclin B1 and fourteen other TAAs were detected by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 464 sera from patients with PCa, benign prostatic hyperplasia (BPH), and other controls. Autoantibodies to cyclin B1 were detected in 31.0% of sera from randomly selected patients with PCa versus 4.8% in sera with BPH. In the further analysis, 31.4% of sera from PCa patients at the early stage contained anti-cyclin B1 autoantibody, and even 29.4% of patients who had normal prostate-specific antigen (PSA) levels in their serum samples were observed anti-cyclin B1 positive. The cumulative positive rate of autoantibodies against seven selected TAAs (cyclin B1, survivin, p53, DFS70/LEDGFp75, RalA, MDM2, and NPM1) in PCa reached 80.5%, significantly higher than that in normal control sera. In summary, autoantibody to cyclin B1 might be a potential biomarker for the immunodiagnosis of early stage PCa, especially useful in patients with normal PSA level. This study further supports the hypothesis that a customized TAA array can be used for enhancing anti-TAA autoantibody detection, and it may constitute a promising and powerful tool for immunodiagnosis of PCa.

The miR-21 potential of serving as a biomarker for liver diseases in clinical practice

2020 ◽  
Vol 48 (5) ◽  
pp. 2295-2305
Author(s):  
Jiawei Zhang ◽  
Dandan Li ◽  
Rui Zhang ◽  
Peng Gao ◽  
Rongxue Peng ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Diseases ◽  
Hepatic Disease ◽  
Noninvasive Detection ◽  
Diagnosis And Prognosis ◽  
Expected Performance ◽  
Potential Biomarker ◽  
Disease Condition ◽  
Complex Regulatory Network

The role of miR-21 in the pathogenesis of various liver diseases, together with the possibility of detecting microRNA in the circulation, makes miR-21 a potential biomarker for noninvasive detection. In this review, we summarize the potential utility of extracellular miR-21 in the clinical management of hepatic disease patients and compared it with the current clinical practice. MiR-21 shows screening and prognostic value for liver cancer. In liver cirrhosis, miR-21 may serve as a biomarker for the differentiating diagnosis and prognosis. MiR-21 is also a potential biomarker for the severity of hepatitis. We elucidate the disease condition under which miR-21 testing can reach the expected performance. Though miR-21 is a key regulator of liver diseases, microRNAs coordinate with each other in the complex regulatory network. As a result, the performance of miR-21 is better when combined with other microRNAs or classical biomarkers under certain clinical circumstances.

Tumor-Associated Antigens

JAMA ◽  
1973 ◽  
Vol 223 (2) ◽  
pp. 174 ◽  
Author(s):  
Stanley E. Order
Keyword(s):  
Tumor Associated Antigens

Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in an elderly population

VASA ◽  
2014 ◽  
Vol 43 (3) ◽  
pp. 189-197 ◽  
Author(s):  
Yiqiang Zhan ◽  
Jinming Yu ◽  
Rongjing Ding ◽  
Yihong Sun ◽  
Dayi Hu
Keyword(s):  
High Density Lipoprotein ◽  
Total Cholesterol ◽  
High Density Lipoprotein Cholesterol ◽  
Ankle Brachial Index ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
Cholesterol Ratio ◽  
Potential Biomarker

Background: The associations of triglyceride (TG) to high-density lipoprotein cholesterol ratio (HDL‑C) and total cholesterol (TC) to HDL‑C ratio and low ankle brachial index (ABI) were seldom investigated. Patients and methods: A population based cross-sectional survey was conducted and 2982 participants 60 years and over were recruited. TG, TC, HDL‑C, and low-density lipoprotein cholesterol (LDL-C) were assessed in all participants. Low ABI was defined as ABI ≤ 0.9 in either leg. Multiple logistic regression models were applied to study the association between TG/HDL‑C ratio, TC/HDL‑C ratio and low ABI. Results: The TG/HDL‑C ratios for those with ABI > 0.9 and ABI ≤ 0.9 were 1.28 ± 1.20 and 1.48 ± 1.13 (P < 0.0001), while the TC/HDL‑C ratios were 3.96 ± 1.09 and 4.32 ± 1.15 (P < 0.0001), respectively. After adjusting for age, gender, body mass index, obesity, current drinking, physical activity, hypertension, diabetes, lipid-lowering drugs, and cardiovascular disease history, the odds ratios (ORs) with 95 % confidence intervals (CIs) of low ABI for TG/HDL‑C ratio and TC/HDL‑C ratio were 1.10 (0.96, 1.26) and 1.34 (1.14, 1.59) in non-smokers. When TC was further adjusted, the ORs (95 % CIs) were 1.40 (0.79, 2.52) and 1.53 (1.21, 1.93) for TG/HDL‑C ratio and TC/HDL‑C ratio, respectively. Non-linear relationships were detected between TG/HDL‑C ratio and TC/HDL‑C ratio and low ABI in both smokers and non-smokers. Conclusions: TC/HDL‑C ratio was significantly associated with low ABI in non-smokers and the association was independent of TC, TG, HDL‑C, and LDL-C. TC/HDL‑C might be considered as a potential biomarker for early peripheral arterial disease screening.

ProSP-B as a potential biomarker in diffuse parenchymal lung disease (DPLD)

Pneumologie ◽  
2012 ◽  
Vol 66 (06) ◽  
Author(s):  
N Kahn ◽  
A Rossler ◽  
K Hornemann ◽  
T Muley ◽  
A Warth ◽  
...  
Keyword(s):  
Lung Disease ◽  
Potential Biomarker ◽  
Diffuse Parenchymal Lung Disease ◽  
Parenchymal Lung Disease ◽  
Parenchymal Lung

Secretome profiling identifies T-Cadherin as a potential biomarker for adipose tissue plasticity

2018 ◽  
Author(s):  
S Göddeke ◽  
B Knebel ◽  
P Fahlbusch ◽  
T Hörbelt ◽  
G Poschmann ◽  
...  
Keyword(s):  
Adipose Tissue ◽  
Potential Biomarker ◽  
Secretome Profiling
Sign in / Sign up

Export Citation Format

Share Document